A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance

Hee Seung Lee¹, Soo Been Park¹, Sun A Kim¹, Sool Ki Kwon², Hyunju Cha², Do Young Lee², Seonggu Ro², Joong Myung Cho² & Si Young Song¹

Pancreatic cancer is predominantly lethal, and is primarily treated using gemcitabine, with increasing resistance. Therefore, novel agents that increase tumor sensitivity to gemcitabine are needed. Histone deacetylase (HDAC) inhibitors are emerging therapeutic agents, since HDAC plays an important role in cancer initiation and progression. We evaluated the antitumor effect of a novel HDAC inhibitor, CG200745, combined with gemcitabine/erlotinib on pancreatic cancer cells and gemcitabine-resistant pancreatic cancer cells. Three pancreatic cancer-cell lines were used to evaluate the antitumor effect of CG200745 combined with gemcitabine/erlotinib. CG200745 induced the expression of apoptotic proteins (PARP and caspase-3) and increased the levels of acetylated histone H3. CG200745 with gemcitabine/erlotinib showed significant growth inhibition and synergistic antitumor effects in vitro. In vivo, gemcitabine/erlotinib and CG200745 reduced tumor size up to 50%. CG200745 enhanced the sensitivity of gemcitabine-resistant pancreatic cancer cells to gemcitabine, and decreased the level of ATP-binding cassette-transporter genes, especially multidrug resistance protein 3 (MRP3) and MRP4. The novel HDAC inhibitor, CG200745, with gemcitabine/erlotinib had a synergistic anti-tumor effect on pancreatic cancer cells. CG200745 significantly improved pancreatic cancer sensitivity to gemcitabine, with a prominent antitumor effect on gemcitabine-resistant pancreatic cancer cells. Therefore, improved clinical outcome is expected in the future.

Pancreatic cancer is the most lethal cancer with poor prognosis. Patients with locally advanced disease have a median survival time of 8–12 months, and patients with distant metastases have significantly worse outcomes, with a median survival time of only 3–6 months¹. At present, gemcitabine-based regimens are considered standard treatment for pancreatic cancer patients. Recently, gemcitabine plus nab-paclitaxel showed minimal improvements in overall survival with a median survival approaching one year in patients with advanced pancreatic cancer². Despite these advances in gemcitabine-based treatment, the number of pancreatic cancer-related deaths and chemotherapy refractory pancreatic cancer has continued to increase³. Since the resistance of pancreatic cancer negatively affects the therapeutic effects of gemcitabine, agents that increase tumor sensitivity and overcome drug resistance to gemcitabine are needed.

Histone deacetylase (HDAC) inhibitors are the most developed anti-cancer drugs targeting epigenetic modulation. In normal cells, histone acetylation is precisely controlled by histone acetyl transferase (HAT) and HDAC. However, hyper-acetylation of oncogenes or hypo-acetylation of tumor suppressor genes is frequently observed in cancer cells⁴. HDAC inhibitors acetylate the lysine residues at the histone N-terminal tail, and loosen the association of histones with DNA, thereby inducing the expression of genes related to tumor suppression and differentiation. Therefore, HDAC inhibition offers potential as an effective cancer treatment⁵⁶. To date, two HDAC inhibitors, vorinostat and romidepsin, have been approved by the Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma. Regarding pancreatic cancer, previous studies showed that HDAC inhibitors show in vitro and in vivo anti-tumor effects⁷⁻¹⁰.

¹Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.  
²CrystalGenomics, Inc., 5F, Bldg A, Korea Bio Park, Seongnam, Korea. Correspondence and requests for materials should be addressed to S.Y.S. (email: sysong@yuhs.ac)
CG200745, (E)-N(1)-(3-(dimethylamino)propyl)-N(8)-hydroxy-2-((naphthalene-1-loxy) methyl) oct-2-enediamide, is a recently developed HDAC inhibitor\(^4\). Similar to other inhibitors, such as vorinostat and belinostat, the novel HDAC inhibitor, CG200745, is an intravenous hydroxamate-based pan-HDAC inhibitor. Its inhibitory effect on cell growth has been demonstrated in several types of cancer cells, including prostate cancer, renal cell carcinoma, and colon cancer in mono- and combinational-therapy with other anticancer drugs\(^4\). CG200745 was five times more effective than vorinostat in acetylating histone H3 in colon cancer-cell lines, and induced the acetylation of the tumor suppressor, p53, and cancer cell death\(^1\).

Combination therapy using gemcitabine/erlotinib is an approved standard chemotherapy in patients with advanced pancreatic cancer, but has marginal therapeutic benefits\(^1\). To improve the therapeutic results, we investigated the anti-tumor effect of CG200745 combined with gemcitabine/erlotinib in pancreatic cancer cells. We also evaluated whether CG200745 could overcome the resistance to gemcitabine in human gemcitabine-resistant pancreatic cancer cells.

**Results**

**Effect of CG200745 on growth inhibition and cell death in pancreatic cancer cells.** As shown in Fig. 1A, CG200745 dose-dependently decreased pancreatic cancer cell viability. To determine the inhibitory effects of CG200745 on cell proliferation, we measured the IC\(_{50}\) of CG200745 in pancreatic cancer cells. BxPC3 were more sensitive to the growth-inhibitory effect of CG200745 (IC\(_{50}\) 2.4 µM) than Cfpac-1 and HPAC (IC\(_{50}\) 10.7 and 7.4 µM, respectively). To assess the effects of CG200745 on HDACs in pancreatic cancer cells, we measured histone H3 acetylation levels. Treatment of pancreatic cancer cells with the IC\(_{50}\) of CG200745 caused a significant increase in histone H3 acetylation within 24 h of treatment (Fig. 1B). Doses of erlotinib and CG200745 equivalent to IC 20–30 were selected to minimize individual cytotoxic effect and know the combinatory anticancer effect on the pancreatic cancer cell lines, respectively (Fig. 1 and Supplementary Fig. 1). The effect of CG200745 on pancreatic cancer cell apoptosis was also tested. Western blot analysis indicated that CG200745 increased the expression of pro-apoptotic proteins, BAX, and p21 (Fig. 1B).

**Synergistic inhibitory and apoptotic effect of CG200745 combined with gemcitabine/erlotinib in pancreatic cancer cells.** BxPC3, Cfpac-1, and HPAC cell lines were treated with gemcitabine, erlotinib,
and CG200745. The results from the cell viability indicated that the anti-proliferative effect of CG200745 with gemcitabine/erlotinib was significantly higher than that of other combinations (Fig. 2 and Supplementary Fig. 2). Western blot analysis showed the apoptotic protein, cleaved caspase-3, in a triple combination line. A low CG200745 concentration, with a combination of gemcitabine or erlotinib, significantly increased the antitumor effect, and was most effective when combined with both regimens.

Flow cytometry was performed to examine the apoptotic rate of BxPC3 cells 72 h after CG200745 administration by using the Annexin V-FITC/PI double staining method (Fig. 3). The results of flow cytometry showed that CG200745 treatment increased the number of Annexin V-positive BxPC3 cells, indicating apoptosis induction. Notably, cell exposure to CG200745 resulted in enhanced accumulation of autophagic, late apoptotic cells. Flow cytometry results showed that CG200745 combined with gemcitabine/erlotinib treatment increased the number of Annexin V-positive BxPC cells, indicating apoptosis activation. CG200745 sensitized pancreatic cancer cells to the anti-proliferative effects of gemcitabine and erlotinib. The interaction between CG200745 and gemcitabine/erlotinib was further analyzed using the Chou–Talalay method, to determine whether this combination exhibited additive or synergistic cytotoxicity. Using CompuSyn software, we calculated the Combination index (CI) according to concentrations of CG200745, gemcitabine, and erlotinib, which revealed that this combination was synergistic in the three cell lines. Moreover, the CIs of triple combinations showed better synergism than that of other combinations (Supplementary Table 1).

**Combination effect of CG200745 with gemcitabine/erlotinib in a xenograft model.** As shown in Fig. 4, the BxPC3 xenograft growth in nude mice was dramatically inhibited by the co-administration of CG200745 and gemcitabine/erlotinib. Combined gemcitabine/erlotinib and CG200745 reduced the tumor volume up to 50% by 3 weeks in the BxPC3 xenograft model.

**Growth inhibition by CG200745 in gemcitabine-resistant pancreatic cancer cells.** Gemcitabine-resistant cells were very insensitive to the growth-inhibitory effect of gemcitabine. The IC_{50} of gemcitabine in gemcitabine-resistant cells was 0.595 and 7.654 μM, which was 24.5-fold and 7.9-fold higher than that of parent cell lines Cfpac-1 and HPAC, respectively. However, the treatment with CG200745 in gemcitabine-resistant pancreatic cancer cells eliminated the chemo-resistance (Supplementary Fig. 3). The IC_{50}
of CG200745 in gemcitabine-resistant cells was 9.8 and 6.8 μM, which was 0.8-fold and 0.9-fold lower than that of parent cell lines Cfpac-1 and HPAC, respectively. CG200745 sensitized gemcitabine-resistant pancreatic cancer cells to the anti-proliferative effects of gemcitabine and erlotinib. The anti-proliferative effect of the triple combination was most effective in gemcitabine-resistant Cfpac-1- and HPAC-cell lines and CIs revealed that this combination was strongly synergistic (Fig. 5).

The agarose gel electrophoresis of the MRP family revealed that CG200745 treatment decreased the mRNA levels of ABC transporter genes, especially MRP3 and MRP4 (Fig. 6A and B). Western blot analysis showed significantly reduced MRP4 expression in gemcitabine-resistant pancreatic cancer-cell lines (Fig. 6C and D). It was hypothesized that gemcitabine sensitivity could be increased in combination with CG200745. These preclinical results show that combined treatment of CG200745 and gemcitabine/erlotinib potentiated the anti-tumor effects in gemcitabine-resistant pancreatic cancer cells.

Discussion
Aberrant expression of HDACs represents an attractive therapeutic target for pancreatic cancer. Since HDAC inhibitors can reactivate epigenetically silenced genes, they could be used in pancreatic cancer as anticancer agents. Previously, several HDAC inhibitors have been studied for the inhibition of pancreatic cancer cells. Trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) strongly inhibited the growth of pancreatic cancer cells by inducing cell-cycle arrest and apoptosis16. Recently, the synergistic effects of HDAC inhibitors and conventional chemotherapeutic agents have been studied 17, which showed that a combination of gemcitabine and HDAC inhibitors potently enhanced growth inhibition and apoptosis in pancreatic cancer cells18. To the best of our knowledge, this is the first study to show the anticancer effects of a new HDAC inhibitor, CG200745, on pancreatic cancer cells. In the present study, CG200745 combined with conventional chemotherapeutic regimens, gemcitabine/erlotinib, dramatically inhibited pancreatic cancer-cell proliferation in vitro and in vivo. Furthermore, CG200745 enhanced the sensitivity of gemcitabine-resistant pancreatic cancer cells to gemcitabine treatment.

A limited efficacy in solid tumors and undesirable adverse reactions of HDACIs were reported in previous clinical studies20. For example, Richards et al. 21 showed the anticancer effect of the combination of the HDAC inhibitor, CI-994, and gemcitabine in pancreatic cancers; patients receiving CI-994 combined with gemcitabine had a higher incidence of grade 3/4 adverse events such as thrombocytopenia, anemia, and leukopenia than those treated with only gemcitabine. However, CG200745 was well tolerated at the tested doses with no dose-limiting toxicities in the first human study. Only grade 3/4 hematologic toxicities were reported, such as anemia and
Figure 4. CG200745 inhibits the growth of pancreatic tumors in nude mice. (A) Relative tumor volume with gemcitabine, erlotinib, and CG200745 treatments. (B) Relative tumor weight with gemcitabine, erlotinib, and CG200745 treatments. Cell line: BxPC-3; animal: Balb/c nude mouse, female, 6 w; dosing schedule: 3 weeks; CG200745: 30 mg/kg, IP, daily; erlotinib: 50 mg/kg, PO, daily; gemcitabine, Gem: 20 mg/kg, IP, day 1, 4, 7, 10, 13, 16, 19.

Figure 5. Synergistic effect of CG200745 in combination with gemcitabine/erlotinib in gemcitabine-resistant pancreatic cancer cells (A, Cfpac-1; B, HPAC). The anti-proliferative effect of CG200745 combined with gemcitabine/erlotinib is more than the effect of gemcitabine/erlotinib without CG200745 in gemcitabine-resistant pancreatic cancer cells. * or **Indicates significant differences compared with control (p < 0.05 or p < 0.01). G, gemcitabine; CG, CG200745; E, erlotinib.
neutropenia, which did not last more than one week. Other toxicities included Grade 1/2 mild fatigue and anorexia.

Gemcitabine-based regimens remain a major chemotherapy for pancreatic cancer, but the resistance to gemcitabine has negatively affected the overall survival in cancer patients. Drug resistance is attributable to several processes occurring in neoplastic cells. One of these processes is decreased drug accumulation within cancer cells because of an increased drug efflux. Specifically, the ATP-binding cassette transporter family C (ABCC) is responsible for mediating multidrug resistance. Human ABCC consists of 12 members, 9 of which comprise a group of multidrug-resistant proteins (MRP1–MRP9, ABCC1–ABCC6, and ABCC10–ABCC12). In the present study, CG200745 decreased the mRNA transcripts and its corresponding protein for MRP4 in vitro. Therefore, CG200745 controlled the drug efflux and sensitivity in gemcitabine-resistant pancreatic cancer cells. Improvement of resistance to gemcitabine allows this drug to be used more effectively to treat pancreatic cancer.

The HDAC family is a multiclass consisting of 18 HDACs divided into four subgroups by cell localization, role, and structure: class I including HDAC 1, 2, 3, and 8 (localized in the nucleus); class II HDACs including 4, 5, 6, 7, 9, and 10 (localized in both the nucleus and cytoplasm); class III HDACs consists of sirtuins (1–7); and class IV includes HDAC 11. Similar to the overexpression of HDAC1 in gastric cancer, and HDAC2 and HDAC3 in colon cancer, HDAC7 is over-expressed in pancreatic cancer. Approximately 81% of the PDAC tissue samples displayed increased HDAC7 mRNA and protein expressions. Therefore, previous studies showed that HDAC7 could be critical in tumor growth and metastasis, and a clinically beneficial biomarker for pancreatic cancer diagnosis and prognosis. In the present study, high levels of HDAC7 mRNA and protein were detected in pancreatic cancer cells (Supplementary Fig. 4). The inhibitory effect of our novel compound on HDAC7 in pancreatic cancer cells was considerable.

In conclusion, the novel HDAC inhibitor, CG200745, showed an antitumor effect in three types of pancreatic cancer cell lines and synergized the antitumor effect of gemcitabine and erlotinib, which are conventional chemotherapeutic regimens for pancreatic cancer cells. We also showed that the CG200745 combined treatment induced cell death in gemcitabine-resistant cells, suggesting that CG200745 can overcome gemcitabine resistance. Resolving the problem of drug resistance to conventional therapies is a key factor for improving

Figure 6. Agarose gel electrophoresis of the MRP family members indicates mRNA expression in gemcitabine-resistant pancreatic cancer cells. CG200745 treatment decreases mRNA levels of ABC transporter genes, especially MRP3 and MRP4 (A, C: Cfpac-1; B, D: Hpac). Western blot analysis of MRP4 expression in gemcitabine resistant cells after CG200745 treatment.
pancreatic cancer prognosis. Our data provided evidence that CG200745 could potentially improve the treatment of gemcitabine-resistant pancreatic cancer. CG200745 combined with standard gemcitabine-based chemotherapy could be used as a successful combination therapy in the future.

**Methods**

**Chemicals.** CG200745 was provided by CrystalGenomics Inc. (Seoul, Rep. Korea)\(^{11,12}\). A 50-mM stock solution for biological assays was prepared in dimethyl-sulfoxide (DMSO) and stored at −20 °C until use. Erlotinib was purchased from ApexBio (ApexBio Technology, Houston, TX, USA), and gemcitabine was supplied by Eli Lilly Korea (Seoul, Korea).

**Cell lines.** Three pancreatic cancer-cell lines, BxPC3, Cfpac-1, and HPAC, were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). BxPC-3 cells were grown in RPMI1640 (Invitrogen Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Hyclone, Logan, Utah, USA), CFPAC-1 cells were grown in IMDM (Invitrogen Gibco) with 10% FBS (Hyclone), and HPAC cells were grown in DMEM/F12 (Invitrogen Gibco) with 10% FBS (Hyclone). Cells were maintained in a humidified incubator with 5% CO\(_2\) at 37 °C.

**Cell viability assay.** Cells were seeded at 3–5 × 10\(^3\)/well in 96 well plates and exposed to various concentrations of compounds for 72 h. Cell viability effects of CG200745, gemcitabine, and erlotinib were assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Amresco, Solon, OH, USA) assay. IC\(_{50}\) values were reached when cell growth was inhibited at 50% of the DMSO control. Values are the means of triplicate wells from three independent experiments for each drug concentration.

**Western blotting.** Cells were lysed in a lysis buffer containing 70 mM glycerophosphate (pH 7.2), 0.6 mM Na vanadate, 2 mM MgCl\(_2\), 1 mM EGTA, 1 mM DTT, 0.5% Triton X-100, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), and 1 × complete protease inhibitor (Roche Applied Science, Nutley, NJ, USA). Protein (25 μg) was resolved on SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon-P, Millipore, Bedford, MA, USA). The membranes were blocked in 5% (w/v) nonfat dry milk (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and incubated with the following primary antibodies: mouse monoclonal anti-HDAC1, mouse monoclonal anti-HDAC2, mouse monoclonal anti-HDAC3, rabbit monoclonal anti-HDAC4, rabbit monoclonal anti-HDAC6, rabbit polyclonal anti-phospho-AKT, rabbit polyclonal anti-phospho-ERK (Cell Signaling Technology, Inc., Danvers, MA, USA), mouse monoclonal anti-HDAC7, rabbit polyclonal anti-EGFR, rabbit polyclonal anti-acetylated histone h3, rabbit polyclonal anti-c-met, mouse monoclonal anti-caspase3, rabbit polyclonal anti-p21, rabbit polyclonal anti-BAX, rabbit polyclonal anti-AKT, rabbit polyclonal anti-ERK, mouse monoclonal anti-MRP4, and mouse monoclonal anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After incubation with appropriate horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology), immunoblots were developed with the West Pico Chemiluminescent substrate (Thermo Scientific, Rockford, IL, USA).

**Semi-quantitative RT-PCR.** Total RNA was extracted using an RNeasy mini kit (QIAGEN, Hilden, Germany), and cDNA was synthesized using a Superscript II system (Invitrogen) according to manufacturer’s protocols. Beta-actin (ACTB) was used as a reference gene. The primers are listed in Supplementary Table 2.

**Immunofluorescence.** Cells were grown on coverslips and treated with indicated concentrations of compounds for 48 h. Cells were fixed with 4% paraformaldehyde and incubated with blocking buffer (1 × PBS/5% normal donkey serum/0.3% Triton X-100). Cells were stained with rabbit polyclonal anti-cleaved caspase-3 (1:400, Cell Signaling Technology, Inc.) overnight at 4 °C. Stained cells were incubated with goat anti-rabbit Alexa 488-conjugated secondary antibody (Jackson ImmunoResearch Inc., West Grove, PA, USA) for 1 h. Nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI). The stained cells were analyzed on an Olympus BX51 microscope and images were captured using an Olympus DP71 camera (Olympus America Inc., Center Valley, PA, USA).

**Apoptosis.** Apoptosis was detected by flow cytometry through Annexin V-FITC/propidium iodide (PI) staining. Cells (2 × 10\(^6\) cells per well) were seeded on 6 well plates and incubated overnight at 37 °C. The compound was added and cells were incubated for a further 72 h. Trypsinized cells were harvested, with 100 μl 1× binding buffer. Harvested cells were incubated with 1 μg/ml FITC-labeled Annexin V (BD Biosciences, San Diego, CA) and 2.5 μg/ml PI at room temperature of 25 °C for 15 min in the dark. Flow cytometric measurement of the stained cells was performed with BD LSRII (BD Bioscience, San Jose, CA).

**Xenograft mouse model.** Experiments carried out using 6-week-old male BALB/c nude mice (Japan SLC, Inc., Japan) were approved by the Institutional Animal Care and Use Committee (IACUC) of Biototech Co., Ltd. based on the Animal Protection Act. All experiments were performed in accordance with relevant guidelines and regulations. Exponentially grown BxPC3 cells (5 × 10\(^6\) cells/mouse) were s.c. injected into the right flank. Treatment started two weeks after the tumor implant, when tumors reached a volume of approximately 100 mm\(^3\). Gemcitabine (20 mg/kg) was administered i.p. for three weeks (day 1, 4, 7, 10, 13, 16, 19). Erlotinib (50 mg/kg) was administered p.o. daily for three weeks. CG200745 (30 mg/kg) was administered i.p. daily for 3 weeks. Tumor formation was monitored twice a week by measuring the width and length of the mass, and tumor volume (TV) was calculated using the formula "TV (mm\(^3\)) = (L × W\(^2\))/2," with L as the largest and W as the smallest diameters. Animals were sacrificed after three weeks from the first administration.
Gemcitabine-resistant pancreatic cancer-cell lines. Gemcitabine-resistant pancreatic cancer cells were established by escalating doses of gemcitabine serially in HPAC and CFPC-1 cells. Initially, cells were cultured for 72 h with IC$_{50}$ of gemcitabine with a defined drug-free interval. As cells adapted to the dose, the gemcitabine concentration was serially doubled. Finally, after cells recovered from 10μM gemcitabine treatment, 100μM of the drug was added to the medium to eradicate most of the cell population.

Combination studies. The effectiveness of chemotherapeutic agents used in this study in combination, was analyzed using CompuSyn software. CI values were calculated to confirm synergy. CI between 0.9 and 1.1 indicates addictive effects, and CI > 1.1 indicates antagonistic effects.

Statistics. Statistical analyses were performed using SPSS 18.0 software. All values were expressed as the mean ± standard deviation. Comparisons between two groups were analyzed using t-tests. Values of $P < 0.05$ were considered significant.

References

1. Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N Engl J Med 371, 1039–1049 (2014).
2. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369, 1691–1703 (2013).
3. Siegel, L. R., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J Clin 65, 5–29 (2015).
4. Chou, T. C. Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One 10, e0119379 (2015).
5. Chen, C. H. et al. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clin Cancer Res 20, 1274–1287 (2014).
6. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1, 287–299 (2002).
7. Iwahashi, S. et al. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-alpha on pancreatic cancer cells. Int J Clin Oncol 16, 671–679 (2011).
8. Damaskos, C. et al. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer. Anticancer Res 35, 3129–3135 (2015).
9. Dovzhanskyy, D. I. et al. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer 12, 226 (2012).
10. Feng, W. et al. Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. Biomembr, 257–264 (2015).
11. Oh, E. T. et al. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells. Invest New Drugs 30, 435–442 (2012).
12. Hwang, C. J. et al. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing McI-1 and Bcl-XL. Invest New Drugs 30, 1434–1442 (2012).
13. Kim, K. P. et al. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies. Invest New Drugs 33, 1048–1057 (2015).
14. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group. Journal of Clinical Oncology 25, 1960–1966 (2007).
15. Chou, T. C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Research 70, 440–446 (2010).
16. Garcia-Morales, P. et al. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther 4, 1222–1230 (2005).
17. Feng, W. et al. Histone deacetylase inhibitors induce apoptosis and cell death in gemcitabine-resistant pancreatic cancer cells. Biochem Biophys Res Commun 343, 95–101 (2013).
18. Donadelli, M. et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773, 1095–1106 (2007).
19. Kelly, W. K. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 17, 1096–1102 (2006).
20. Komi, J. et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115, 359–367 (2005).
21. Ellis, L. & Pili, R. Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 1, 2411–2469 (2010).
22. Ouaisi, M. et al. High histone deacetylation (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 15, 2318–2328 (2008).
23. Zhu, C. et al. The role of histone deacetylation 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Med Med (Berl) 89, 279–289 (2011).
24. Deer, E. L. et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39, 425–435 (2010).
25. Pili, R. et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumors. Br J Cancer 106, 77–84 (2012).
26. Duxbury, M. S. et al. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10, 2307–2318 (2004).
27. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmaco 58, 621–681 (2006).

Acknowledgements

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1324).
Author Contributions
S.Y.S., S.B.P., D.Y.L. and H.C. designed studies; S.B.P., S.A.K., H.C., S.K.K. and H.S.L. performed experiments and prepared all the figures; S.B.P., H.C., H.S.L., D.Y.L. and S.Y.S. analyzed data; H.S.L., S.B.P., S.A.K., S.K.K., H.C., D.Y.L., S.R., J.M.C. and S.Y.S. wrote the paper. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Lee, H. S. et al. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Sci. Rep. 7, 41615; doi: 10.1038/srep41615 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017